PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or Higher Risk MDS

          This is a first-in-human dose escalation/dose expansion study to evaluate the safety and identify the best dose (or recommended Phase 2 dose) of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or recurred acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS). Autologous CAR T cells are modified immune cells that have been engineered in the laboratory to specifically target a protein found on tumor cells and kill them.